eLearning PET Pearls | Imaging interpretation supporting diagnostic investigation

eLearning PET Pearls | Imaging interpretation supporting diagnostic investigation is organized by Springer Healthcare IME.

About the Program:
An interactive perceptual activity to guide and improve the analysis of different PET trace results.

You will be asked to annotate potential abnormalities and receive video feedback from the experts to help build your confidence to accurately detect the early signs of mild cognitive impairment.

eLearning PET Pearls is part of the medical education program, Preparing for the new era of neuroimaging for Alzheimer's disease

During this time of rapid evolution and discovery in Alzheimer’s disease, neuroimaging is expected to play a critical role in clinical practice.

By participating in our expert-led program you will gain valuable insights into the utilization and interpretation of different tracers and biomarkers, enabling earlier detection of Alzheimer’s disease as well as identifying those who would benefit from novel disease-modifying therapies.

Program Director and Chair Frederik Barkhof is joined by Lyduine Collij, Alexander Drzezga, and Silvia Morbelli.

Discover the latest breakthroughs, connect with leading experts, and discuss the evolving role of PET imaging in the diagnosis and treatment of Alzheimer’s disease.

The introduction of pathology-specific disease-modifying therapies has highlighted the important contribution of PET imaging in detecting the early signs of mild cognitive impairment.

With a heterogeneous clinical population, the interpretative process has formidable challenges. The routine application of PET tracers in current clinical settings revolves around subjective visual appraisal and subsequent binary classification of scans. 

PET techniques centered around amyloid and tau are being applied in clinical settings, and require the expertise of nuclear medicine and radiology physicians.

As new data emerges on novel PET biomarkers and tracers, our program will disseminate key insights and evidence-led guidance to help advance diagnostic accuracy and disease modification for Alzheimer’s disease.

This independent educational program is designed for global (excl. UK) nuclear medicine physicists and radiologists.

After participating in the program, learners will be able to:

1. Explain the critical role of PET imaging in the new era of disease modification of Alzheimer’s disease
2. Appraise the utility of current and emerging PET biomarkers in clinical practice
3. Identify patterns from different PET tracers for a negative and positive AD brain and debate methods beyond binary amyloid PET interpretation

This program is aligned with Springer Medicine – an English-language, medical education platform provided by the Springer Nature Group. Springer Medicine supports doctors in their ongoing quest for optimal patient care, and delivers the latest evidence on new therapies, practice guidelines and news in easily digestible formats to keep healthcare professionals effortlessly up to date.

This activity is supported by an educational grant from Lilly.